Neural Therapeutics Inc.
NURL
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.95% | -47.06% | -110.32% | 33.72% | 29.42% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,258.24% | 954.02% | 800.72% | 116.93% | 133.38% |
| Change in Net Operating Assets | -78.57% | -40.38% | 19.91% | -9.38% | 25.53% |
| Cash from Operations | -465.21% | 5.44% | 27.89% | 81.47% | 88.93% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 842.73% | 146.67% | 137.77% | -1.94% | -89.88% |
| Repurchase of Common Stock | 44.12% | 44.12% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -205.56% | -223.53% | 100.00% | 100.00% |
| Cash from Financing | 1,400.00% | 250.54% | 279.10% | 20.47% | -105.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 146.55% | 144.11% | 181.00% | 9,781.25% | -237.13% |